NBIX

#760
Neurocrine Biosciences Inc
130.8100 USD
+3.55%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
130.8100
130.8100
Jahresspanne
122.1375
160.1800
Tagesänderung
+3.55%
Monatliche Änderung
+0.31%
6 month change
-9.79%
Jahresänderung
-9.79%
Vorheriger Schlusskurs
126.3200
Eröffnung
130.8100
Bid
Ask
Tief
130.8100
High
130.8100
Volumen
127
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 13.1285 B
  • Employee 2 000
  • Founded 1992
  • CEO Kevin C. Gorman
  • Website www.neurocrine.com
  • Headquarter Delaware, United States
  • FIGI BBG000GJS7C1
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
30.37
Preis-Umsatz-Verhältnis
5.08

Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Nachrichten